Arbutus Biopharma Corp
F:I9DN
Arbutus Biopharma Corp
F:I9DN
Price:
3.91
EUR
-2.01%
Market Closed
Market Cap:
€737.9m
Add Note
Add Target
Capture your thoughts and set a target
Decide at what price you'd be comfortable buying and we'll help you stay ready.
Based on
Margin of Safety
0%
10%
20%
30%
40%
50%
Your Price Target
Linked to
current price
· In Buy Zone
Loading
Note attached
Choose the stock you wish to monitor with a price target
Recently Viewed
|
A
|
Arbutus Biopharma Corp
F:I9DN
|
US |
|
A
|
Asset Five Group PCL
SET:A5
|
TH |
|
C
|
Castle Peak Holdings PCL
SET:CPH
|
TH |
|
Vertical Exploration Inc
XTSX:VERT
|
CA |
|
S
|
Sri Trang Agro Industry PCL
SET:STA
|
TH |
|
M
|
Monnari Trade SA
WSE:MON
|
PL |
|
MM Rubber Company Ltd
BSE:509196
|
IN |
|
W
|
WOW Factor PCL
SET:W
|
TH |
|
B
|
BBI Buergerliches Brauhaus Immobilien AG
F:BBI
|
DE |
Wall St Price Targets
I9DN Price Targets Summary
Arbutus Biopharma Corp
Arbutus Biopharma Corp
Wall Street analysts forecast I9DN stock price to rise over the next 12 months.
According to Wall Street analysts, the average 1-year price target for I9DN is 4.67 EUR with a low forecast of 4.63 EUR and a high forecast of 4.81 EUR.
Lowest Forecast
Price Target
4.63
EUR
18% Upside
Average Forecast
Price Target
4.67
EUR
19% Upside
Highest Forecast
Price Target
4.81
EUR
23% Upside
Why do you have more estimates than other sites?
Our estimates are sourced from the pool of sell-side and buy-side analysts that we have access to. What you see on other sites is mostly sourced from sell-side analysts.
What is I9DN's stock price target?
Price Target
4.67
EUR
4.67
EUR
According to Wall Street analysts, the average 1-year price target for I9DN is 4.67 EUR with a low forecast of 4.63 EUR and a high forecast of 4.81 EUR.
What is the Revenue forecast for Arbutus Biopharma Corp?
Projected CAGR
-56%
-56%
Over the last 13 years, the compound annual growth rate for Revenue has been 0%. The projected CAGR for the next 2 years is -56%.
